Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Dow
Baxter
Johnson and Johnson
Harvard Business School
AstraZeneca
McKesson

Last Updated: December 7, 2019

DrugPatentWatch Database Preview

Details for Patent: 5,532,241

See Plans and Pricing

« Back to Dashboard

Which drugs does patent 5,532,241 protect, and when does it expire?

Patent 5,532,241 protects VIIBRYD and is included in one NDA.

This patent has thirty-two patent family members in nineteen countries.

Summary for Patent: 5,532,241
Title: Piperidines and piperazines
Abstract:Piperidine and piperazine derivatives of the formula I ##STR1## wherein Ind is an indol-3-yl radical which is unsubstituted or mono- or polysubstituted by OH, OA, CN, Hal, COR.sup.2 or CH.sub.2 R.sup.2, R.sup.1 is benzofuran-5-yl or 2,3-dihydrobenzofuran-5-yl, chroman-6-yl, chroman-4-on-6-yl, 3-chromen-6-yl or chromen-4-on-6-yl, which is unsubstituted or monosubstituted by CN, CH.sub.2 OH, CH.sub.2 OA or COR.sup.2, Q is C.sub.m H.sub.2m, N or CR.sup.3, A is alkyl having 1-6 C atoms, Hal is F, C1, Br or I, R.sup.2 is OH, OA, NH.sub.2, NHA or NA.sub.2, R.sup.3 is H, OH or OA and m is 2, 3 or 4, and their physiologically acceptable salts, are active on the central nervous system.
Inventor(s): Bottcher; Henning (Darmstadt, DE), Seyfried; Christoph (Seeheim-Jugenheim, DE), Bartoszyk; Gerd (Darmstadt, DE), Greiner; Hartmut (Darmstadt, DE)
Assignee: Merck Patent Gesellschaft mit beschrankter Haftung (Darmstadt, DE)
Application Number:08/314,734
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 5,532,241
Patent Claim Types:
see list of patent claims
Compound; Composition;

Drugs Protected by US Patent 5,532,241

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Allergan Sales Llc VIIBRYD vilazodone hydrochloride TABLET;ORAL 022567-001 Jan 21, 2011 AB RX Yes Yes   Start Trial   Start Trial Y Y   Start Trial
Allergan Sales Llc VIIBRYD vilazodone hydrochloride TABLET;ORAL 022567-002 Jan 21, 2011 AB RX Yes No   Start Trial   Start Trial Y Y   Start Trial
Allergan Sales Llc VIIBRYD vilazodone hydrochloride TABLET;ORAL 022567-003 Jan 21, 2011 AB RX Yes No   Start Trial   Start Trial Y Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 5,532,241

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Germany43 33 254.4Sep 30, 1993

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
Boehringer Ingelheim
Merck
Express Scripts
AstraZeneca
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.